Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis

Hiroshi Kakeya; Yoshitsugu Miyazaki; Hisato Senda; Tsutomu Kobayashi; Masafumi Seki; Koichi Izumikawa; Kazunori Yanagihara; Yoshihiro Yamamoto; Takayoshi Tashiro; Shigeru Kohno

doi:10.1128/AAC.01369-07

Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis

Antimicrob Agents Chemother. 2008 May;52(5):1868-70. doi: 10.1128/AAC.01369-07. Epub 2008 Feb 25.

Authors

Hiroshi Kakeya¹, Yoshitsugu Miyazaki, Hisato Senda, Tsutomu Kobayashi, Masafumi Seki, Koichi Izumikawa, Kazunori Yanagihara, Yoshihiro Yamamoto, Takayoshi Tashiro, Shigeru Kohno

Affiliation

¹ Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. kakeya@nagasaki-u.ac.jp

Abstract

SPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).

Publication types

Comparative Study

MeSH terms

Amphotericin B / pharmacology*
Animals
Antifungal Agents / pharmacology
Aspergillosis / drug therapy*
Aspergillosis / microbiology
Aspergillus flavus / drug effects
Disease Models, Animal
Dose-Response Relationship, Drug
Echinocandins / pharmacology*
Lipopeptides
Lipoproteins / pharmacology*
Lung Diseases, Fungal / drug therapy*
Lung Diseases, Fungal / microbiology
Male
Micafungin
Mice
Polyenes / pharmacology*
Treatment Outcome

Substances

Antifungal Agents
Echinocandins
Lipopeptides
Lipoproteins
Polyenes
liposomal amphotericin B
SPA S 843
Amphotericin B
Micafungin